Heart Genomics wins state cash for heart failure Dx development

Florida's Heart Genomics secured a new state investment it will use to develop molecular diagnostic tests for heart failure patients. The Institute for the Commercialization of Public Research, a nonprofit state entity launched in 2007, is providing the undisclosed funding amount. Heart Genomics describes the new cash infusion as "matching funding." The new diagnostic tests are based on work developed at the University of Miami's Interdisciplinary Stem Cell Institute. Release

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.